Nautilus Biotechnology, Inc.
NAUT· Nasdaq
NAUTNautilus Biotechnology, Inc.
Filed Apr 30, 2024 · 10-Q · 30 days after period end · 0001808805-24-000041
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Net Income | -$18.73M | -$14.97M | -$15.76M | -$8.41M |
| EPS Diluted | -$0.15 | -$0.12 | -$0.13 | -$0.25 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR
ended Mar 31, 2024 · filed Apr 30, 2024 · 30 d after period end
